CLDX completed enrollment in Phase 3 CSU studies with topline data expected Q4 2026, while R&D expenses surged 50% and net losses increased 64% as the company advances multiple clinical programs for barzolvolimab.
The completion of Phase 3 enrollment in CSU represents a major operational milestone that moves CLDX closer to potential commercialization of its lead asset, with sustained efficacy data showing over 40% of patients maintaining complete response 7 months post-dosing. However, the company is burning significant cash across multiple concurrent clinical trials in various indications, creating execution risk and increased capital requirements as it approaches critical data readouts.
The financial picture reflects a clinical-stage biotech in heavy investment mode, with R&D expenses jumping 50% to $245M driving net losses up 64% to $259M, while operating cash burn increased 34% to $211M. Current assets declined 28% to $535M and stockholders' equity fell 29% to $527M, indicating substantial cash consumption that will likely require additional financing before the critical Q4 2026 CSU data readout. Revenue doubled but remains immaterial at $1.8M, highlighting the company's complete dependence on successful clinical execution for future value creation.
Strong top-line growth of 87.5% — accelerating demand or successful expansion into new markets.
Net income declined 63.9% — review whether driven by operations, interest costs, or non-recurring items.
R&D investment increased 49.8% — signals commitment to future product development, though near-term margin impact.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Capital expenditure jumped 41.4% — major investment cycle underway; assess returns on deployment.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Operating cash flow fell 33.7% — earnings quality concerns; investigate working capital changes and non-cash items.
Equity decreased 29.4% — buybacks or losses reducing book value, monitor solvency ratios.
Current liabilities rose 29.1% — increased short-term obligations, watch current ratio.
Current assets declined 28.4% — monitor working capital adequacy and short-term liquidity.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →